Is SLGL's Q4 2024 EPS forecast too conservative?

**Sol-Gel Technologies' (SLGL) Q4 2024 EPS forecast appears to be conservative.** Here's why:

1. **Historical Performance**: SLGL has surpassed consensus EPS estimates two times over the last four quarters. This indicates a trend of exceeding expectations, which suggests that the company's performance could be stronger than the conservative forecast implies.
2. **Revenue Outlook**: The company's revenue for Q3 2024 exceeded analyst estimates by 28%. This robust revenue growth suggests that SLGL has the potential to exceed EPS forecasts as well.
3. **Improvement in Financial Performance**: SLGL's net loss narrowed by 94% from Q3 2023 to Q3 2024, and the company reported a positive EPS of $0.013 in Q3 2024, improved from a $0.20 loss in the same quarter of the previous year. This significant improvement in financial health supports the notion that the company's EPS could be higher than the conservative forecast.
4. **Market Conditions**: The pharmaceutical industry is experiencing a 10% growth forecast. Given SLGL's focus on dermatology products and its positive revenue trajectory, it is plausible that the company could outperform the industry average and exceed the conservative EPS forecast.

In conclusion, while a conservative forecast is reasonable given the uncertainties in financial projections, the company's historical performance, revenue outlook, and recent improvements in financial health suggest that SLGL's Q4 2024 EPS forecast might be on the lower side.